Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From UDG Healthcare plc

Private Equity Eyes Pharma As Vectura Gets Snapped Up By Carlyle

Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.

M & A Respiratory

Shire/TKT: The Price of Diversification

Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.

BioPharmaceutical Strategy

Pliva: Two Steps Forward, One Step Back?

After a fervent US expanstion capped by the surprise $150 million licensing of Indevus OAB treatment Sanctura, proprietary ambitions at the Croatian generics play Pliva may be stalling. Sanctura sales have disappointed, illustrating again the challenges of taking a specialist approach to primary care marketing. Pliva's best bet may be to switch growth engines to its promising biogenerics portfolio.

BioPharmaceutical Strategy

Biogenerics: A Step Closer

Progress on biogenerics inches along, as evidenced by deal between Barr Pharmaceuticals and PLIVA giving Barr rights to market Pliva's version of G-CSF in North America, and by the recent well-attended FDA workshop on follow-on proteins (FOPs). Barr/PlLIVA, the first company/company deal in this field in months indicates that companies still see opportunity despite last year's regulatory setbacks. The FDA workshop, while far from conclusive, hinted at a softening of positions by both opponents and proponents of biogenerics; at least they're talking the same language.

BioPharmaceutical Legal Issues
See All

Company Information

  • Industry
  • Distributors
  • Services
  • Services
    • Managed Care, Insurance, Integrated Systems
    • Outcomes Studies
    • Services sold to health care facilities
    • Specialized outpatient services
    • Utilization Review, Claims Processing, Cost Contai
    • Managed Care, Insurance, Integrated Systems
      • Specialized Provider Networks
UsernamePublicRestriction

Register